Literature DB >> 28765910

EVI5 is a novel independent prognostic predictor in hepatocellular carcinoma after radical hepatectomy.

Jintian Tang1, Jianghua Ou2, Chunyan Xu1, Chao Yi1, Feng Xue1, Lin Xu1, Fenju Lai3, Jianjun Tang4, Shengping Li5, Tiebang Kang5, Wei Ding1, Boqing Wang1.   

Abstract

The present study explored the correlation of ecotropic viral integration site 5 (EVI5) expression with clinicopathological features and prognosis in hepatocellular carcinoma (HCC). A total of 205 HCC patients were included retrospectively. Quantitative real-time polymerase chain reaction (RT-qPCR) and western blotting were performed to detect the profile of EVI5 expression in HCC cell lines and fresh tissues. Archived paraffin-embedded specimens were investigated for EVI5 expression by immunohistochemistry (IHC). Both the mRNA and protein levels of EVI5 were obviously upregulated in HCC cell lines and tumor tissues. EVI5 protein level was closely associated with the clinicopathological characteristics, including liver function (P=0.013), venous invasion (P=0.015) and TNM stage (P=0.014). Furthermore, univariate analysis showed that the patients with high EVI5 expression indicated shorter overall survival (OS, P<0.001) and recurrence-free survival (RFS, P=0.001) than those with low EVI5 expression. Importantly, high EVI5 expression also exerts predictive power for higher postoperative recurrence rate by stratified analysis. Multivariate Cox regression analysis demonstrated that OS was correlated with both tumor number (P=0.046) and EVI5 expression (P<0.001) and that RFS was correlated with serum AFP (P=0.023), tumor number (P=0.036) and EVI5 expression (P<0.001). Taken together, EVI5 is an useful independent prognostic marker of survival and recurrence in hepatocellular carcinoma.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28765910     DOI: 10.3892/or.2017.5862

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  3 in total

1.  EVI5 is an oncogene that regulates the proliferation and metastasis of NSCLC cells.

Authors:  Tingting Cai; Jieqi Zhou; Yuanyuan Zeng; Wenwen Du; Yang Zhang; Ting Liu; Yulong Fu; Jian-An Huang; Qian Qian; Jianjie Zhu; Chunhua Ling; Zeyi Liu
Journal:  J Exp Clin Cancer Res       Date:  2020-05-11

2.  The Evi5 oncogene promotes laryngeal cancer cells proliferation by stabilizing c-Myc protein.

Authors:  Cheng-Gang Mao; Xiao-Chun Zhou; Yi-Dao Jiang; Li-Jia Wan; Ze-Zhang Tao; Jun Guo
Journal:  Cancer Cell Int       Date:  2020-02-07       Impact factor: 5.722

3.  circEVI5 acts as a miR-4793-3p sponge to suppress the proliferation of gastric cancer.

Authors:  Meinan Yan; Liling Niu; Jing Liu; Yuan Yao; Hui Li
Journal:  Cell Death Dis       Date:  2021-08-05       Impact factor: 9.685

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.